https://savvysciencepublishers.com/index.php/jodt <p>The "Journal of Ocular Diseases and Therapeutics (JODT)" has discontinued publication and is not accepting new submissions. <br />All previously published articles remain accessible in the archive of the journal.</p> Savvy Science Publishers en-US Journal of Ocular Diseases and Therapeutics 2309-6136 https://savvysciencepublishers.com/index.php/jodt/article/view/904 <p>Diabetes has been recognized by the World Health Organization (WHO) as a noncommunicable, chronic disease and a 21st century epidemic. Diabetic retinopathy (DR) is one of the three leading causes of blindness among the working-age population aged 20 to 74 years.</p> <p>Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients, and the impact of DME on quality of life is very significant. Currently, first-line treatment recommendations for center-involved DME (CI-DME) include intravitreal anti-VEGF injections on a monthly or bimonthly regimen. It is essential to understand the burden that treatment regimens have on patients, as well as on healthcare systems. The most significant improvement to the regimen would be to have fewer injections and monitoring visits while maintaining satisfactory vision outcomes. A lower number of intravitreal injections could optimize disease outcomes by improving patient compliance.</p> <p>This article discusses novel agents targeting alternative pathways and mechanisms involved in the pathogenesis of DME, as well as high-dose drugs and novel approaches to treatment regimens aimed at extending treatment intervals, decreasing treatment burden, and increasing treatment efficacy. This knowledge will enhance the selection of treatments, thereby improving patient compliance with therapy and optimizing healthcare system resources.</p> Anna Nowińska Copyright (c) 2023 2023-05-03 2023-05-03 10 1 10 10.12974/2309-6136.2023.10.01 https://savvysciencepublishers.com/index.php/jodt/article/view/953 <p><em>Aim: </em>To report the outcomes of internal revision with bleb needling in cases of failing blebs with the internal sclerostomy blocked by iris tissue.</p> <p><em>Methods:</em> Prospective study of 26 eyes of 26 patients with failing blebs where target IOP was not achieved with 2 anti-glaucoma drugs and sclerostomy was blocked by iris (confirmed on gonioscopy). Patients were divided into 3 groups depending on the time from the first surgery- early (&lt;3 months), intermediate (4-12 months) and late (&gt;1 year). Patients underwent internal revision with bleb needling with either 5-Fluorouracil (5-FU) or Mitomycin C (MMC)</p> <p><em>Results:</em> 26 eyes of 26 patients were included in the study. Mean age was 51.35±14.5 years. Time from the filtration surgery was early in 3, intermediate in 5 and late in 18 eyes. Mean IOP reduction at 3 months was 32±18% with maximum reduction in early group (40%). Mean IOP decreased from 24.5±3.4 mmHg to 16.2±4.3 mmHg in 5-FU group (12 patients) and 27.4±9 mmHg to 18.2±6.6 mmHg in MMC group (14 patients). Self-limiting complications were hyphema in 2 patients and subconjunctival haemorrhage in 1 patient.</p> <p><em>Conclusion:</em> Internal revision with bleb needling is a safe and effective procedure for reviving failing blebs.</p> Kirti Singh Neha Sachdev Arshi Singh Copyright (c) 2023 2023-11-24 2023-11-24 10 11 15 10.12974/2309-6136.2023.10.02